Becton Dickinson To Spin Diabetes Care Unit In 2022 forbes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forbes.com Daily Mail and Mail on Sunday newspapers.
Published: May 10, 2021
May 10, 2021 11:00 UTC
Finerenone significantly reduced the risk of the composite primary endpoint of cardiovascular death and non-fatal cardiovascular events versus placebo when added to standard of care
1
FIGARO-DKD is the second positive Phase III study within the finerenone study program in CKD and T2D to meet its primary endpoint
1,2,3
Bayer’s Phase III cardiovascular outcomes study FIGARO-DKD, evaluating the efficacy and safety of the investigational drug finerenone versus placebo when added to standard of care in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) has met its primary endpoint. The study showed finerenone significantly reduced the composite risk of time to first occurrence of cardiovascular (CV) death or non-fatal CV events (myocardial infarction, stroke, or hospitalization for heart failure). The Phase III FIGARO-DKD study included more patients with earlier stage CKD and T2D compared to the FIDELIO-DKD stu
Metabolisches Syndrom: Was Diagnose bedeutet - und welche Therapie nötig ist focus.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from focus.de Daily Mail and Mail on Sunday newspapers.
Mumbai-based Fitterfly is providing 360-degree guidance to help people control diabetes May 7, 2021
Founded in 2016, digital therapeutics startup Fitterfly offers guidance on nutrition, exercise, sleep, stress, and other factors to help people better manage lifestyle diseases, including diabetes, PCOS, and obesity, among others. 128 CLAPS
128
Lifestyle diseases like diabetes are a growing concern in India. According to International Diabetes Federation, in 2020,
India was home to over 77 million diabetes patients.
Entrepreneur and surgeon
Dr Arbinder Singal explains that people with diabetes need handholding and care after they are diagnosed with the disease. Along with medicines and treatment, they need help with staying fit, maintain a healthy lifestyle, and work on controlling or reversing it.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Lilly collaborates internationally with leading diabetes technology companies to integrate connected insulin pen solutions for people with diabetes
May 6, 2021 GMT
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company) (PRNewsfoto/Eli Lilly and Company)
INDIANAPOLIS, May 6, 2021 /PRNewswire/ With a goal of integrating data and technology to help streamline diabetes management, Eli Lilly and Company (NYSE: LLY) signed strategic international agreements with four companies – DexCom, Inc., Glooko Inc., myDiabby Healthcare and Roche – to advance connected solutions and streamline care for people living with diabetes in markets outside of the United States. These companies offer unique diabetes management platforms that will be compatible with Lilly’s Tempo Pen™ (approved in several global markets) and Tempo Smart Button™ (currently in late-stage development) to support peo